Stephen Remondi

CEO & Founder at Xsphera Biosciences Inc

📍 Winchester, Massachusetts, United States🔄 Updated September 2026💼 3 investments📅 8 years investing🗓 Last invested Sep 2021
Operator-angel🌍 United States
3
Total investments
2
Early stage
1
Mid stage
0
Late stage
8y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
Sep 2021
Epistemix enables organizations to improve forecasts and manage risks by using interactive synthetic populations to test strategies impacting health, economic, social, and environmental outcomes.
Board Member
Nov 2019
AEYE Health is a venture-backed digital health startup that developed AI algorithms that provide immediate, totally autonomous, point-of-care interpretation of fundus images for various conditions.
Board Member
Oct 2018
ZwitterCo's membrane technologies maintain unprecedented fouling resistance and chemical tolerance, operating for years in what have historically been unfilterable process waters and wastewaters. Our mission is to make it practical for industries to recycle water and enhance product recovery with breakthrough advancements in filtration. To learn more, please visit our website at www.zwitterco.com or reach out at info@zwitterco.com.
Experience · 6 entries
All (6)
Investments (3)
Founder (2)
Board (3)
2021
Board Member
Sep 2021
Epistemix enables organizations to improve forecasts and manage risks by using interactive synthetic populations to test strategies impacting health, economic, social, and environmental outcomes.
2019
Board Member
Nov 2019
AEYE Health is a venture-backed digital health startup that developed AI algorithms that provide immediate, totally autonomous, point-of-care interpretation of fundus images for various conditions.
2018
CEO & Founder
Nov 2018
About Xsphera Biosciences envisions a world where failure is no longer the most likely outcome in oncology clinical trials. Our ex vivo platform, invented at the Dana-Farber Cancer Institute, is a powerful integration of biology and cloud computing that accelerates drug development. Xsphera uniquely enables the study of single-variable testing, which is not possible with in vivo studies. Human Tissue Predicts Human Response Drug testing is dominated by in vivo tests of engineered mice - which are notoriously poor predictors of drug performance. Xsphera believes human tissue is the best predictor of human response. High quality, human tissue samples are sourced from our clinical network. Xsphera then captures the entirety of each patient’s tumor microenvironment in microfluidic devices. Each channel is treated with different therapeutics and multiple endpoints are measured including immune stimulation and tumor cell death. Unlock the Mysteries of Drug Mechanisms Xsphera unlocks the mysteries of drug mechanisms with our cloud platform that integrates complex multi-omic response data for each patient into a unified, intelligent interface. This accelerates scientific understanding of why patients respond to or resist therapies. Improved understanding leads to reduced clinical failure rates. With Xsphera, novel therapeutics move into the clinic with confidence. Turn Overwhelming Data into Rapid Understanding Drug developers are confronted with vast amounts of overwhelming and scattered data as they attempt to extract scientific understanding from study analytics. As a result, unquantifiable volumes of valuable study data sit un-analyzed on hard drives. With Xsphera, no data is left behind. Our cloud-based platform ingests and integrates tissue, patient and results data into a single unified source. AI-driven algorithms automate deep analysis and put previously unknowable insights within reach.
Board Member
Oct 2018
ZwitterCo's membrane technologies maintain unprecedented fouling resistance and chemical tolerance, operating for years in what have historically been unfilterable process waters and wastewaters. Our mission is to make it practical for industries to recycle water and enhance product recovery with breakthrough advancements in filtration. To learn more, please visit our website at www.zwitterco.com or reach out at info@zwitterco.com.
R-Cubed Capital Partners LP
General Partner
Sep 2018
Show all 6 entries ↓
Investment activity
2018–2021 · 3 investments
201812019120211
Recent (last 2 years)Earlier